KemPharm, a specialty pharmaceutical company with operations in Coralville, has been delisted from trading on the Nasdaq market, effective at the beginning of trading today. The company will trade under its same ticker symbol, "KMPH," on the OTC Markets Venture Market (OTCQB). According to a filingwith the U.S. Securities and Exchange Commission, the company received a letter from Nasdaq on May 19 that it would be delisted because it was unable to regain compliance with the market’s $35 million minimum value for listed securities. Earlier this month the company reported a net loss of $5.8 million for its fiscal first quarter, with first-quarter revenue of $2.1 million from research and development services as compared with fourth-quarter revenue of $1.4 million.